FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

Go back to FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
(NASDAQ: LQDA) Delayed: 66.88 -1.51 (2.21%)
Previous Close $68.39    52 Week High
Open $68.08    52 Week Low
Day High $68.72    P/E N/A 
Day Low $66.57    EPS
Volume 3,896,375